DE69925134D1 - Rekombinante adenovirus für gewebespezifische genexpression ins herz - Google Patents

Rekombinante adenovirus für gewebespezifische genexpression ins herz

Info

Publication number
DE69925134D1
DE69925134D1 DE69925134T DE69925134T DE69925134D1 DE 69925134 D1 DE69925134 D1 DE 69925134D1 DE 69925134 T DE69925134 T DE 69925134T DE 69925134 T DE69925134 T DE 69925134T DE 69925134 D1 DE69925134 D1 DE 69925134D1
Authority
DE
Germany
Prior art keywords
recombinant adenovirus
tissue
heart
gene expression
specific gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69925134T
Other languages
English (en)
Other versions
DE69925134T2 (de
Inventor
Kenneth R Chien
Yibin Wang
Sylvia Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE69925134D1 publication Critical patent/DE69925134D1/de
Application granted granted Critical
Publication of DE69925134T2 publication Critical patent/DE69925134T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69925134T 1998-09-11 1999-09-10 Rekombinante adenovirus für gewebespezifische genexpression ins herz Expired - Lifetime DE69925134T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9996098P 1998-09-11 1998-09-11
US99960P 1998-09-11
PCT/US1999/020730 WO2000015821A1 (en) 1998-09-11 1999-09-10 Recombinant adenovirus for tissue specific expression in heart

Publications (2)

Publication Number Publication Date
DE69925134D1 true DE69925134D1 (de) 2005-06-09
DE69925134T2 DE69925134T2 (de) 2006-01-19

Family

ID=22277433

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925134T Expired - Lifetime DE69925134T2 (de) 1998-09-11 1999-09-10 Rekombinante adenovirus für gewebespezifische genexpression ins herz

Country Status (10)

Country Link
US (1) US6451594B1 (de)
EP (1) EP1109925B1 (de)
JP (1) JP2002525064A (de)
CN (1) CN1159445C (de)
AT (1) ATE294874T1 (de)
AU (1) AU5819599A (de)
CA (1) CA2342283C (de)
DE (1) DE69925134T2 (de)
HK (1) HK1039795A1 (de)
WO (1) WO2000015821A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
CZ20031569A3 (cs) * 2000-12-07 2003-11-12 Gencell S. A. Polynukleotidy obsahující fragment sekvence v protisměru od genu CARP, vektory a expresní kazety, které je obsahují, a jejich použití
EP1477556A1 (de) * 2003-05-16 2004-11-17 Heart Biosystems GmbH Verfahren zur Selektion von kardiomyogenen Zellen oder Herzmuskelzellen aus gemischten Zellpopulationen
WO2005023292A1 (en) * 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
US8859273B2 (en) * 2003-12-24 2014-10-14 Medtronic, Inc. Methods of using HCN genes to treat cardiac arrhythmias
US20050244377A1 (en) * 2003-12-24 2005-11-03 Daniel Sigg Methods of treating cardiac disorders by suppressing the expression of the potassium inwardly-rectifying channel
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US11512326B2 (en) 2009-05-26 2022-11-29 University Of Florida Research Foundation, Incorporated Small angiotensin peptide expression system in mammalian cells
PL3254703T3 (pl) * 2011-04-22 2020-10-05 The Regents Of The University Of California Wiriony wirusa towarzyszącego adenowirusom z różnymi kapsydami i sposoby ich zastosowania
KR20140035967A (ko) * 2011-05-26 2014-03-24 유니버시티 오브 워싱톤 세포 및 유전자에 기반한 심장 기능을 개선하는 방법
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
CA2940513C (en) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
CA2907799A1 (en) 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
WO2015124546A1 (en) * 2014-02-19 2015-08-27 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic Aav vectors for the treatment of ischemic and non-ischemic heart disease
EP3107939B1 (de) 2014-02-19 2020-06-17 University of Florida Research Foundation, Inc. Abgabe einer nrf2-therapie zum schutz gegen reaktive sauerstoffspezies
WO2015138628A1 (en) 2014-03-11 2015-09-17 University Of Florida Research Foundation, Inc. Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
CA2942776C (en) 2014-03-17 2023-01-24 Adverum Biotechnologies, Inc. Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
JP6577960B2 (ja) * 2014-04-22 2019-09-18 メディツィニッシュ ホホシュール ハノーバー 心肥大の治療および診断のためのｌｎｃＲＮＡ
KR20170137730A (ko) 2015-03-02 2017-12-13 애드베룸 바이오테크놀로지스, 인코포레이티드 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
AU2016235163B2 (en) 2015-03-24 2022-03-24 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
CN105754997B (zh) * 2016-03-30 2019-02-26 华中农业大学 狂犬病毒drv-ah08株的先导rna及其在制备预防与治疗狂犬病毒的药品中的应用
MX2019001276A (es) 2016-07-29 2019-06-13 Univ California Viriones de virus adenoasociados con cápside variante y métodos para su uso.
WO2018075798A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
EP3676373A4 (de) 2017-08-28 2021-06-09 The Regents of The University of California Capsid-varianten von adeno-assoziierten viren und verfahren zur verwendung davon
CN110823870A (zh) * 2018-08-10 2020-02-21 武汉大学人民医院（湖北省人民医院） 一种基于上转化发光技术的心脏节律与功能的光控制系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE307212T1 (de) * 1992-11-18 2005-11-15 Arch Dev Corp Adenovirus-gelenkter gen-transfer zum herz-und glatten vaskulären muskel
US5747245A (en) 1994-06-14 1998-05-05 La Jolla Cancer Research Foundation Nucleic acids encoding Fas associated proteins and screening assays using same
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1998010088A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US5772993A (en) 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues

Also Published As

Publication number Publication date
ATE294874T1 (de) 2005-05-15
US6451594B1 (en) 2002-09-17
CN1159445C (zh) 2004-07-28
CA2342283A1 (en) 2000-03-23
WO2000015821A1 (en) 2000-03-23
DE69925134T2 (de) 2006-01-19
EP1109925A1 (de) 2001-06-27
EP1109925B1 (de) 2005-05-04
CN1325451A (zh) 2001-12-05
JP2002525064A (ja) 2002-08-13
HK1039795A1 (zh) 2002-05-10
AU5819599A (en) 2000-04-03
CA2342283C (en) 2004-05-25

Similar Documents

Publication Publication Date Title
DE69925134D1 (de) Rekombinante adenovirus für gewebespezifische genexpression ins herz
Saaristo et al. Adenoviral VEGF‐C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes
William Petersen et al. The plasticity of human breast carcinoma cells is more than epithelial to mesenchymal conversion
Ye et al. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer
Rosenbloom et al. Extracellular matrix 4: the elastic fiber
Korhonen et al. Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization
Nusse The int genes in mammary tumorigenesis and in normal development
JP2001524828A (ja) 切断型ｖｅｇｆ関連蛋白質
ATE260974T1 (de) Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
BR0110090A (pt) Proteìna, processos para hidrolisar ligações beta-glucosìdicas e beta-xilosìdicas e para produzir um polipeptìdeo, sequência de ácido nucleico, construção de ácido nucleico, cepa microbiana recombinante, e, sonda de oligonucleotìdeo
WO2002012523A3 (en) CELL TYPE SPECIFICITY GENE DELIVERY VECTORS FOR PRIMARY HUMAN CHONDROCYTES
ES2331441T3 (es) Dna que codifica dp-75 y un proceso para su uso.
RU2019142845A (ru) Вирусная экспрессионная конструкция, содержащая кодирующую последовательность фактора роста фибробластов 21 (fgf21)
Gruss et al. Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice
ATE312935T1 (de) Regulatorische sequenzen für die in-vivo- expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.
RU2005137697A (ru) Синтетический ген, кодирующий человеческий раково-эмбриональный антиген, и его применение
CN102127546A (zh) 一种骨骼肌特异性actin启动子及其应用
Zheng et al. Evaluation of salivary gland acinar and ductal cell-specific promoters in vivo with recombinant adenoviral vectors
EP1203819A3 (de) Entzündungshemmende Vektoren
NZ529915A (en) Stimulation of vascularization of ischemic tissue by angiogenesis with VEGF-B186
CN111465697B (zh) 用于预防或治疗心力衰竭的药物组合物
Wang et al. Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer
PE20010610A1 (es) Vectores adenovirales recombinantes y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar y cicatrices hipertroficas
Sadano et al. Newly identified type of β actin reduces invasiveness of mouse B16‐melanoma
WO2002002148A3 (en) Dual recombinant gene therapy compositions and methods of use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition